Search Details

Word: researchers (lookup in dictionary) (lookup stats)
Dates: all
Sort By: most recent first (reverse)


Usage:

...worth pursuing in a significant way. They also question whether such a large trial can be considered as a proof of concept. "Doing a 16,000-person trial, it can't be a proof of concept at that point," says Dr. David Ho, director of the Aaron Diamond AIDS Research Center in New York City. "Would I invest in it? The answer is no. There are other things that are more likely to work, that are better, easier and more straightforward than this vaccine...

Author: /time Magazine | Title: Behind the Rising Doubts About Hailed AIDS Vaccine | 10/13/2009 | See Source »

...vaccine's effect is small, but believes that it's an important first step toward understanding how the body fights off HIV. "It's barely significant, yes," he says. "But it's interesting in that it opens up a door for us to be able to pursue more research." Although the number of volunteers who were protected were few, they are still the first who may have been protected at all by an AIDS vaccine and are therefore considered a valuable starting point...

Author: /time Magazine | Title: Behind the Rising Doubts About Hailed AIDS Vaccine | 10/13/2009 | See Source »

Still, the manner in which the trial results were released raised suspicions among some in the AIDS-research community. Scientific results are generally vetted in a two-step process: first, they are published in a peer-reviewed journal, which means a panel of scientists has reviewed and evaluated the validity of the study's methods and the authors' conclusions before publication; once published, other research groups repeat or analyze the data in more depth to further ensure that they are legitimate. The results of the AIDS-vaccine trial did not benefit from either leg of this process. The investigators chose...

Author: /time Magazine | Title: Behind the Rising Doubts About Hailed AIDS Vaccine | 10/13/2009 | See Source »

...authors of that Science letter is waiting for the release of the full set of data before acknowledging complete vindication. "I think I will wait until after the Paris meeting next week to see more of the data before making any comments," wrote Dennis Burton, an immunologist at Scripps Research Institute, in an e-mail response to a request for his reaction...

Author: /time Magazine | Title: Behind the Rising Doubts About Hailed AIDS Vaccine | 10/13/2009 | See Source »

While unfortunate, Fauci says the circumstances surrounding the release of the data should not detract from the potential benefit the results may yet extend to AIDS-vaccine research. The trial was never intended to serve as a demonstration of effectiveness to license a new vaccine, he says. As such, it was a proof-of-concept study that showed it is indeed possible to generate an immune response against HIV - even if only a small...

Author: /time Magazine | Title: Behind the Rising Doubts About Hailed AIDS Vaccine | 10/13/2009 | See Source »

Previous | 264 | 265 | 266 | 267 | 268 | 269 | 270 | 271 | 272 | 273 | 274 | 275 | 276 | 277 | 278 | 279 | 280 | 281 | 282 | 283 | 284 | Next